SCN10A — Na_V1.8

SCN10A (NaV1.8) is a lever-L1 non-opioid analgesic target. Its promoter reads γ = 1.3136, placing it on the firing-threshold scale at |h_sp| = 0.579486; the intervention direction is to reduce inward Na⁺; closed-state stabilisation = the realised move. The read is reproducible [V]; the clinical magnitude is open [O].

SCN10A is read from its human promoter by the same deterministic engine used across the map (nearest-neighbour stacking energy → γ = 1.3136; R19 scale → |h_sp| = 0.579486). The read places the gene in lever L1; its selectivity is cited Layer-2 biology, and every clinical magnitude (potency, dose, efficacy, safety) is graded [O].

The read

SCN10A — Na_V1.8 sits in the threshold map at γ = 1.3136, |h_sp| = 0.579486 (barrier 0.431386). It belongs to lever L1; the intervention direction is to reduce inward Na⁺ (TTX-R upstroke); closed-state stabilisation = the realised move.

selectivity (cited) HIGH nociceptor-selective (DRG); FDA-validated peripheral target

burden Tier-1 acute/peripheral (realised case)

Grades

• read [V] reproducible promoter-switch-threshold read
• order [F] forced by reads
• lever [F] structural lever + direction (anchored to cited agents)
• mechanism [F] structural: peripheral current block raises the firing threshold (anchored to cited agents)
• clinical magnitude [O] OPEN — not a voltage, potency, dose, selectivity-in-vivo, or effect

Firewall. γ here is a read of promoter switch-threshold structure only — never this channel's activation voltage, a candidate's potency, a dosing quantity, an in-vivo selectivity, or a clinical effect. Those magnitudes are [O] open.

Source

Akopian 1996 Nature 379:257; suzetrigine FDA 2025-01-30 (VSD2 closed-state) · reproduce the read (engine)

See also: its lever · prioritisation · grading.